Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo

The flavolignan silibinin was studied for its ability to restore drug sensitivity to EGFR-mutant NSCLC xenografts with epithelial-to-mesenchymal transition (EMT)-driven resistance to erlotinib. As a single agent, silibinin significantly decreased the tumor volumes of erlotinib-refractory NSCLC xenog...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Cufí, Sílvia, Bonavia, Rosa, Vazquez-Martin, Alejandro, Oliveras-Ferraros, Cristina, Corominas-Faja, Bruna, Cuyàs, Elisabet, Martin-Castillo, Begoña, Barrajón-Catalán, Enrique, Visa, Joana, Segura-Carretero, Antonio, Joven, Jorge, Bosch-Barrera, Joaquim, Micol, Vicente, Menendez, Javier A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2013
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3748425/
https://ncbi.nlm.nih.gov/pubmed/23963283
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep02459
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak